Metis TechBio Becomes World’s First AI-Driven Nanomedicine Delivery Company to List on HKEX

5Month13Day, METiS TechBioTechnologyOfficially on HKEXListingListed,Become GlobalThe First AI Drug Delivery Stock, and Also the First AI Macromolecule Biopharmaceutical Stock in Hong Kong.

On the first day of listing, METiS TechBioTechOpening ReportHK$28.68, UpperIncrease by 173.14%,Total market value of approximately 33.054 billion Hong Kong dollars.

This time, METiS TechBioFundraising Exceeds21HKD billion,Set a recordThe Largest IPO Fundraising in Hong Kong's Healthcare Sector Since 2026.

AsGlobally Leading AI Driving Nanomedicine Delivery Enterprises,METiS TechBioPharmaceutical Industry“SpaceX”With the goal of, independently developedThe World's FirstAINano Delivery PlatformNanoForge，At the same time, it is alsoThe Only One in the World to Achieve8IndividualCompanies for Precision Organ Targeted Delivery。

METiS TechBio has collaborated with global30METiS TechBio collaborates with top pharmaceutical and biotech institutions in China.2025Annual Company RevenueAchieve1.05100 million yuan,Increased by nearly70Times, with outstanding commercial growth potential.

At the listing ceremony,Dr. Lai Caida, co-founder, chairman and CEO of METiS TechBio, said:

"The future of biomedicine will no longer be just about 'taking medicine when sick.' METiS TechBio’s ambition is to use AI to build nanoscopic rockets, achieving precise navigation within the inner space of the human body's 30 trillion cells. By writing the code of nucleic acids and proteins into cells, we aim to reprogram diseased and aging cells into healthy ones. This is the original aspiration behind our entrepreneurship, and it is the lifelong mission we are committed to."。IPO is a new starting point for us to accelerate forward.，We will not辜负来自各界的支持和厚爱.”

Accompanying"Artificial Intelligence+"Biological economy, innovative drugs, and other national industrial policies continue to advance,AIThe pharmaceutical and drug delivery track is gradually entering a new stage of value realization.

At the same time, METiS TechBio is entering a crucial window period of accelerated pipeline release, expanded global cooperation, and continuous extension of the industrial ecosystem.

"Rocket+"Satellite" Strategy, Multiple Pipelines Accelerate Realization

After successfully going public, the core logic supporting the long-term valuation of METiS TechBio,Ultimately, it still comes back to a key issue.

ItsNanoForgeCan the platform continue to produceInnovative assets with clinical and commercial value, further leading to more industry collaborations and licensing deals.

Since its inception, METiS TechBio has always been anchored “Rocket+Satellite”Core Strategy。"Rocket" RepresentativeAIThe capability of the driven nanodelivery platform; "Satellite" refers to the innovative drug pipeline continuously incubated based on the platform.

The most noteworthy value of METiS TechBio now lies in the fact that its platform capabilities have gradually started to enter the realization phase.

Current Layout of METiS TechBioUltra10Innovative pipeline,1Item is inpre-NDAPhase,3PaymentCandidate Drug Enters Clinical Stage，4The drug is in the preclinical stage., covering multiple directions such as oncology, immunology, and metabolism.

CompanyDrug DevelopmentIn China,MTS-004Already inPre-market Application (pre-NDA) Key Stage, with a high degree of commercial certainty.

MTS-004Is a treatment forPseudobulbar Affect (PBA, commonly known as“Pseudobulbar affect”） 's novel oral candidate drug, which is not only the first domestically producedⅢPhase Clinical TrialAIEmpowering new drug formulations, and it is currently the only one in China.PBATherapeutic Drugs。

InMETiS TechBio's self-developedAINano-Delivery PlatformNanoForgeUnder the empowerment of,MTS-004Only use3months to complete what traditionally requires1-2Years of preclinical formulation development,From project initiation to completionⅢPhase clinical trials only took38Months。

Data shows, by2035In ChinaPBADrug Market ForecastWill reach70100 million yuan. With the first-mover advantage,MTS-004HopefulCapture a significant market share。

At the same time,MTS-004The range of potential indications is also worth noting. Fan Dongsheng, an authoritative expert in ALS and neurological diseases in China, stated in relevant clinical studies,MTS-004Not only forPBAThe symptoms have shown significant improvement, and there is also a positive trend in alleviating patients' swallowing difficulties.

This means that the potential beneficiary population of this product may further expand in the future.

It is worth noting that,MTS-004Completed Outward Licensing Collaboration, Upfront Payment1100 Million Yuan。METiS TechBioOwnSubsequent profit-sharing rights after listing,Expected to achieve"Down Payment+Milestone Payment+Long-term Sales SplitThe multi-level revenue structure.

In addition to this, the successful listing on the Hong Kong Stock Exchange,Will be further enhancedMETiS TechBioSubsequent pipeline advancement capability.

Particularly noteworthy is that METiS TechBioIn Vivo Tumor ImmunotherapyDirection, multiple globally groundbreaking explorations have been conducted.

One of the core pipelinesMTS-105, mainly targeting liver cancer and advanced solid tumors with liver metastasis,Become the world's first to enter the clinical stagemRNAEncodingTCE（TCell Connector) Solid Tumor Therapy.

Currently,TCEIs rapidly becoming the nextPD-1、ADCLater, another important track in the field of tumor immunology that has received much attention, Amgen, Roche, Johnson & Johnson,ModernaGlobal pharmaceutical giants have all accelerated their layout.

While METiS TechBio has chosen a more cutting-edge approach.mRNACodeTCERoute.Compared with traditional proteinsTCEAndCAR-TTherapy,mRNACodingTCEWithout the need for complex in vitro cell preparation processes, it offers advantages such as more convenient drug administration and higher production efficiency.，AndInEffect, as well as in terms of safety and side effect control, also shows greater potential.

Data shows,MTS105Demonstrates Disruptive Advantages in Preclinical Studies，Each mouse was used only once.0.3–0.5 ugThe dose can achieve100%Complete Tumor Clearance。And the drug not only hasStronger liver-targeted expression effect, and has good safety.

Currently, this therapy hasInIITPhase，And obtain the United StatesFDAOrphan Drug Designation,A New Chapter in the Immunotherapy of Solid Tumors Has Begun.

Another HeavyweightTCEPipelineMTS-109，Also inIITClinical Stage。

Compared with traditionalTCEDifferent,MTS-109Adopted ismRNAEncoded TrispecificityTCEDesign. In animal experiments, it can achieve systemic effects at extremely low doses.BThe highly efficient clearance of cells demonstrates the significant potential of next-generation in vivo immunotherapy.

More crucially, this therapy has broad potential for extending its indications. On one hand, it is expected to be applicable to autoimmune diseases such as lupus erythematosus and lupus nephritis; on the other hand, it can also cover conditions like lymphoma and multiple myeloma.BCell-Associated Hematologic Malignancies.

This means that METiS TechBio is not only attempting single-drug development but is also building a more scalable next-generation therapeutic system around an in vivo immunotherapy platform.

In addition,METiS TechBio Also Has Significant Layout in the Metabolic Field，MTS-201Has currently enteredIPhase clinical stage.

MTS-201TheSpecialThe difference is that it is the only one that has entered the clinical stage and has been proven to stimulateGLP-2OralTGR5Agonist.

Relying on a unique gut-targeting mechanism,MTS-201Not only has the potential for weight loss and blood sugar reduction, but also can improve fatty liver (MASH) and promote intestinal repair, showing application prospects for diseases such as short bowel syndrome. Compared with current metabolic therapies that heavily rely on injections,MTS-201Oral administration has obvious advantages in terms of patient compliance, safety, and side effect control.

In summary, METiS TechBio has entered popular fields such as immunity, oncology, and metabolism, but has avoided the homogenization and internal competition of single-target approaches, precisely positioning itself.TGR5 Agonist,mRNA-TCE Frontier and differentiated directions such as solid tumor immunotherapy.

The core logic behind it is also very clear.，ThroughAI+Nano DeliveryTechnologySystem, seeking problems that traditional therapies have yet to truly solve.

Global Capital Consensus, LeadingAIDrug Delivery

Public information shows that this timeIPOTotal18Cornerstone investors participate in the subscription,Total subscription amount approximately1.48Billion USD, accounting for a high proportion of the issued shares54.84%。

Whether it is the number of participating institutions, the diversity of investor structure, or the overall subscription ratio, all have reached record highs in the Hong Kong stock market in recent years.AIPharmaceuticalsBest in FieldLevel.

The world's largest asset management giant, BlackRockIn5000Million USD Leads，At the same timeUBS、Future Assets、OlympusSimilarly, international long-term capital funds have heavily participated.

As for domestic institutions, leading public offering institutions such as China Asset Management, Fullgoal Fund, ICBC Credit Suisse Fund, and E Fund have collectively entered the market with the same shareholding ratio, which is remarkable in Hong Kong's innovative pharmaceuticals sector.IPOChinaExtremely rare。

More notably, national-level funds have also made their first official move.AIPharmaceutical Direction. Guoxin's GF Venture Innovation Investment Fund subscribed to Metis TechBio Co., Ltd. this time.3.71%Equity。CurrentAIAgainst the backdrop where innovative drugs are gradually becoming a core direction of global technological competition, the entry of national capital has further bolstered long-term confidence in the industry across the entire sector.

This shows that institutions both in China and overseas have effectively reached a consensus:Compared to molecular design, drug delivery has become the more critical and bottleneck technology in innovative drug development.

In the past few decades, innovative drugs have been transitioning from simple chemical drugs to more complex biologics, including monoclonal antibodies, bispecific antibodies, peptides,ADC、mRNA、CRA-T......

The more complex the drug, the harder it is to stabilize its efficacy, thus relying more on precise and efficient delivery systems.

And this is also opening up a brand-new era of treatment. In the past, many"Diseases that are 'untreatable' or 'difficult to treat' have long lacked breakthroughs not only because of the absence of effective drugs, but more importantly, due to the lack of ability to truly deliver drugs to target tissues."

However, There have been several significant issues with traditional delivery systems over the long term.，Long R&D cycle and high cost,Many delivery solutions can only adapt to a certain type of drug, making it difficult to form true platform-based capabilities.

At the same time, core global delivery technologies and patents have long been concentrated in the hands of overseas research institutions and multinational pharmaceutical companies. This has also made delivery technology one of the key underlying issues in the development of China's innovative drug industry.

This direction is increasingly entering the strategic vision of the country.

Especially against the backdrop of the ongoing escalation in global technological competition, biomedicine is regarded as a crucial high ground for future industries.AIDelivery platforms and other underlying capabilities are becoming an important part of the industry's self-reliance and controllability.

"The Fifteenth Five-Year Plan for National Economic and Social Development of the People's Republic of China"This top-level design,ClarifiedDigital China Construction, Artificial Intelligence Empowerment, Biomedicine andBiomanufacturingStrategic Direction for Industrial Development.

Therefore, in recent years, the country has focused on nanoDrugThe support for the biopharmaceutical infrastructure platform is also continuously increasing.

METiS TechBio has previously collaborated with the National Center for Nanoscience and Technology to jointly establish"Drug Delivery Nano-Carrier Laboratory"`, and approved`2025Annual Key Laboratory of Beijing. Notably, in the same year269Among the key laboratories approved in China, this laboratory is also the only one focusing on "artificial intelligence+"Biomedical" Cross-Innovation DirectionPlatform。

And the core behind this is METiS TechBio's long-term development.NanoForgePlatform。The technical foundation lies in,METiS TechBio has built a universal typeAINano-deliveryand drug developmentPlatform, paving a development path with more room for imagination.

The platformIntegrationFinishedQuantum Chemistry,AILipidsLarge Model, Dry and Wet LabsTechnology, for small molecules,mRNA、siRNA and other different drug types, toAnd toLiver, lungs, heart, muscles, tumors, immune system, central nervous system, gastrointestinal tract, etc.8IndividualDifferent Target Organs, quickly generate the optimalResearch and Development as well asDelivery Solution.

ThisDriven by Technology, willDevelopment of TargetedLNPThe average time for small molecule formulations has been compressed from several years to2-3Months,Further breaking the limitations of drug types and targeted organs, with coverageGeneralThe Potential of Drug Delivery.

This differentiated positioning has allowed METiS TechBio to break away from homogeneous competition, placing it upstream in the industry ecosystem and establishing an irreplaceable technological position for subsequent commercial expansion.

And with the completion of the IPO, the capital, brand, and global resources brought by the capital market are expected to further push the company's business ecosystem and technology system into a new cycle phase.

On the one hand, the company can leverage its capital strength and industry influence after going public to further expand its global cooperation footprint, attracting more pharmaceutical companies, biotech firms, and research institutions into the ecosystem.

On the other hand, more collaboration scenarios also mean the accumulation of more real R&D data.，And can also push backAIModel training, lipid library optimization, and delivery system iteration.

Thus, METiS TechBioUltimately formed"Technology Iteration - Commercial Application - Data Feedback"Continuous closed-loop，This is alsoCompanyThe long-term value worth paying attention to.

In conclusion

METiS TechBio has always defined itself as"Pharmaceutical IndustrySpaceX”，This highly technological analogy makes it difficult for many pharmaceutical industry practitioners to intuitively understand its deeper implications.

METiS TechBio is analogous to"Pharmaceutical IndustrySpaceX”，It is not just about relying on dedicated carrier systems on the surface, separately achieving space aerospace transportation and precise delivery of cellular drugs.

The true core commonality between the two lies in:Trying to reconstruct traditional complex industries with high costs and strong experience dependence into a new industrial model that can be engineered and scaled.

SpaceXWhat they do is through reusable rockets, vertical integration, autonomous manufacturing, and rapid iterative testing,Breaking the High in AerospaceHigh, the low-frequency industry status quo, significantly lower the threshold for aerospace entry, and open up a vast commercial aerospace market.

METiS TechBioThroughLong-term layout of nano-delivery,AILipid Large ModelAnd AutomationDry and WetExperimental capability, in essence, is precisely about trying to establish such a set of foundational abilities.，Lower the threshold for drug delivery, enabling patients to access higher-quality and more affordable medications.

And the listing practice of METiS TechBio is preciselyAIA model for the development of the pharmaceutical industry.

AILong surpassing the attributes of traditional R&D tools, it upgrades experiential R&D into a predictable engineering paradigm, spanning the entire process of target discovery, delivery system development, and clinical trials, achieving industrial efficiency improvement and cost reduction.

In the future, as more companies like METiS TechBio come to the forefront, AI-driven drug discovery will no longer be an emerging concept but a decisive force in advancing human health and pushing the boundaries of innovative drug research and development.